These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15287395)

  • 1. Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence.
    Gupta AK; Lynch LE
    Cutis; 2004 Jul; 74(1 Suppl):10-5. PubMed ID: 15287395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciclopirox nail lacquer: a brush with onychomycosis.
    Gupta AK
    Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report.
    Galitz J
    Cutis; 2001 Aug; 68(2 Suppl):23-4. PubMed ID: 11665725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years.
    Sigurgeirsson B; Olafsson JH; Steinsson JT; Kerrouche N; Sidou F
    J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):910-5. PubMed ID: 20028447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.
    Baran R; Kaoukhov A
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):21-9. PubMed ID: 15649187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective.
    Gupta AK; Schouten JR; Lynch LE
    Skin Therapy Lett; 2005 Sep; 10(7):1-3. PubMed ID: 16292454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients at risk of onychomycosis--risk factor identification and active prevention.
    Tosti A; Hay R; Arenas-Guzmán R
    J Eur Acad Dermatol Venereol; 2005 Sep; 19 Suppl 1():13-6. PubMed ID: 16120200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
    Seebacher C; Nietsch KH; Ulbricht HM
    Cutis; 2001 Aug; 68(2 Suppl):17-22. PubMed ID: 11665724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents.
    Gupta AK; Konnikov N; Lynde CW; Summerbell RC; Albreski D; Baran R; Doncker PD; Degreef H
    Eur J Dermatol; 1999 Dec; 9(8):633-8. PubMed ID: 10586132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
    Shemer A; Nathansohn N; Trau H; Amichai B; Grunwald MH
    J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Onychomycosis: Diagnosis and management.
    Singal A; Khanna D
    Indian J Dermatol Venereol Leprol; 2011; 77(6):659-72. PubMed ID: 22016272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options--development of consensus guidelines.
    Lecha M; Effendy I; Feuilhade de Chauvin M; Di Chiacchio N; Baran R;
    J Eur Acad Dermatol Venereol; 2005 Sep; 19 Suppl 1():25-33. PubMed ID: 16120203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of onychomycosis in children.
    Gupta AK; De Rosso JQ
    Postgrad Med; 1999 Jul; Spec No():31-7. PubMed ID: 10492664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Today's treatments options for onychomycosis.
    Iorizzo M; Piraccini BM; Tosti A
    J Dtsch Dermatol Ges; 2010 Nov; 8(11):875-9. PubMed ID: 20738460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onychomycosis in clinical practice: factors contributing to recurrence.
    Scher RK; Baran R
    Br J Dermatol; 2003 Sep; 149 Suppl 65():5-9. PubMed ID: 14510969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of antifungal therapy and the severity index for assessing onychomycosis: part I.
    Baran R; Hay RJ; Garduno JI
    J Dermatolog Treat; 2008; 19(2):72-81. PubMed ID: 18484426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial.
    Grover C; Bansal S; Nanda S; Reddy BS; Kumar V
    Br J Dermatol; 2007 Aug; 157(2):364-8. PubMed ID: 17573877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onychomycosis: Diagnosis, Treatment, and Prevention.
    Beuscher TL; Kelechi TJ
    J Wound Ostomy Continence Nurs; 2019; 46(4):333-335. PubMed ID: 31274864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of onychomycosis: examining the role of monotherapy and dual, triple, or quadruple therapies.
    Gupta AK; Lynch LE
    Cutis; 2004 Jul; 74(1 Suppl):5-9. PubMed ID: 15287394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into the effect of amorolfine nail lacquer.
    Flagothier C; Piérard-Franchimont C; Piérard GE
    Mycoses; 2005 Mar; 48(2):91-4. PubMed ID: 15743424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.